Condition: Acute Lymphoblastic Leukaemia · Acute Myeloid Leukaemia · Higher-risk Myelodysplastic Syndromes · Sponsor: AstraZeneca
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Decatur, Illinois, United States | Recruiting |
| Research Site | New York, New York, United States | Not Yet Recruiting |
| Research Site | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| Research Site | Durham, North Carolina, United States | Recruiting |
| Research Site | Portland, Oregon, United States | Suspended |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Fitzroy, Australia | Suspended |
| Research Site | Perth, Australia | Suspended |
| Research Site | Toronto, Ontario, Canada | Suspended |
| Research Site | Montreal, Quebec, Canada | Suspended |
| Research Site | Copenhagen, Denmark | Recruiting |
| Research Site | Dresden, Germany | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07155226